31-Dec-22 | 31-Dec-21 | 31-Dec-20 | 31-Dec-19 | 31-Dec-18 | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Europe and Rest of the World | 210.00 | 8% | 189.00 | 7% | 159.00 | 7% | 122.00 | 6% | 116.00 | 6% |
Middle East and North Africa | 866.00 | 34% | 847.00 | 33% | 770.00 | 33% | 719.00 | 33% | 656.00 | 32% |
United Kingdom | 8.00 | n/a | 6.00 | n/a | 6.00 | n/a | 7.00 | n/a | 5.00 | n/a |
United States | 1,433.00 | 57% | 1,511.00 | 59% | 1,406.00 | 60% | 1,359.00 | 62% | 1,293.00 | 62% |
Total | 2,517.00 | 100% | 2,553.00 | 100% | 2,341.00 | 100% | 2,207.00 | 100% | 2,070.00 | 100% |
Profit Before Tax | ||||||||||
Unanalysed | 233.00 | 100% | 544.00 | 100% | 558.00 | 100% | 491.00 | 100% | 293.00 | 100% |
Total | 233.00 | 100% | 544.00 | 100% | 558.00 | 100% | 491.00 | 100% | 293.00 | 100% |
31-Dec-22 | 31-Dec-21 | 31-Dec-20 | 31-Dec-19 | 31-Dec-18 | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Branded | n/a | n/a | 669.00 | 26% | 613.00 | 26% | n/a | n/a | 542.00 | 26% |
Generics | 672.00 | 27% | 820.00 | 32% | 744.00 | 32% | n/a | n/a | 692.00 | 34% |
Injectables | 1,141.00 | 63% | 1,053.00 | 41% | 977.00 | 42% | n/a | n/a | 826.00 | 40% |
Unanalysed | 704.00 | n/a | 11.00 | n/a | 7.00 | n/a | n/a | n/a | 10.00 | n/a |
Total | 2,517.00 | 100% | 2,553.00 | 100% | 2,341.00 | 100% | 2,207.00 | n/a | 2,070.00 | 100% |
Profit Before Tax | ||||||||||
Branded | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 111.00 | 24% |
Generics | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 40.00 | 9% |
Injectables | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 305.00 | 67% |
Unanalysed | 233.00 | n/a | 544.00 | n/a | 558.00 | n/a | n/a | n/a | (163.00) | n/a |
Total | 233.00 | n/a | 544.00 | n/a | 558.00 | n/a | 491.00 | n/a | 293.00 | 100% |
You are here: research